We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Increased Bleb Formation Characterizes Metastatic Cancer Cells

By LabMedica International staff writers
Posted on 04 Jun 2019
Print article
Image: Left: Images of a blebbing, highly metastatic PC3 prostate cancer cell (top) and a non-blebbing normal RWPE-1 prostate cell being forced into a microfluidic channel. Middle: Outlines of the images on the left highlighting blebbing and cell deformation. Right: Percentage of highly metastatic PC3, moderately metastatic DU145, and normal RWPE-1 cells that bleb while being forced into a channel along with the standard deviation (SD) (Photo courtesy of Fazle Hussain, Texas Tech University).
Image: Left: Images of a blebbing, highly metastatic PC3 prostate cancer cell (top) and a non-blebbing normal RWPE-1 prostate cell being forced into a microfluidic channel. Middle: Outlines of the images on the left highlighting blebbing and cell deformation. Right: Percentage of highly metastatic PC3, moderately metastatic DU145, and normal RWPE-1 cells that bleb while being forced into a channel along with the standard deviation (SD) (Photo courtesy of Fazle Hussain, Texas Tech University).
A recent paper described an inexpensive fluid biopsy device that is able to distinguish highly metastatic prostate cancer cells from moderately metastatic prostate cancer cells and normal cells.

Since most prostate tumor cells that survive current treatment regimens become metastatic, there is an urgent need for new tools to detect metastatic prostate cancer that do not rely on prostate specific antigen (PSA) measurements, which cannot accurately identify cells with metastatic potential.

Plasma membrane blebbing (in which portions of the cell’s outer layer bulges outward from the more rigid inner layer) is known to provide important metastatic capabilities to cancer cells by aiding cell detachment from the primary tumor site and increasing cell deformability to promote cell migration through the extracellular matrix. In fact, highly metastatic prostate cancer cells flowing through a microfluidic channel form 27% more plasma membrane blebs than normal cells and have a lower stiffness (about 50%).

Taking advantage of this property, investigators at Texas Tech University (Lubbock, USA) developed an instrument that measured bleb formation as the device forced cell samples through minute channels less than 10 microns wide. Results obtained by this method revealed that highly metastatic prostate cancer cells exhibited more blebbing than did moderately metastatic or normal cells. Of the highly metastatic cells 56% produced blebs, whereas only 29% of normal cells and 38% of moderately metastatic cells did.

Mechanistically, increased blebbing by highly metastatic cells was attributed to low levels of the protein F-actin, which resulted in a reduced number of binding sites for proteins that normally anchor the cell’s plasma membrane to the inner cortex.

“This is a potentially significant finding which may provide simple and inexpensive diagnostic methods for detecting early and advanced cancer, particularly metastatic cancer,” said senior author Dr. Fazle Hussain, professor of mechanical engineering at Texas Tech University.

The fluid biopsy device for detection of highly metastatic prostate cancer cells was described in the May 21, 2019, online edition of the journal Biomicrofluidics.

Related Links:
Texas Tech University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.